Skip to main content
Alzheimer DiseaseCognitive functionDrug

What this study is

A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.

What's being tested

  • F 18 T807

    Intervention · DRUG

    Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.

Study details

Official title
F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A
Sponsor
Tammie L. S. Benzinger, MD, PhD
Conditions
Alzheimer Disease
Enrolling
900 people
Starts
2014-10-23
Est. completion
2026-12
Record
View on ClinicalTrials.gov ↗